Expression of fatty acid synthase in nonalcoholic fatty liver disease

URN to cite this document:: urn:nbn:de:bvb:355-epub-370477
DOI to cite this document:: 10.5283/epub.37047

Dorn, Christoph

; Riener, Marc-Oliver ; Kirovski, Georgi ; Saugspier, Michael ; Steib, Kathrin ; Weiss, Thomas S. ; Gäbele, Erwin ; Kristiansen, Glen ; Hartmann, Arndt ; Hellerbrand, Claus

Preview

PDF - Published Version
(318kB)

Date of publication of this fulltext: 10 Apr 2018 12:09

Alternative links to fulltext:Publisher

Details

Item type:	Article
Journal or Publication Title:	International Journal of Clinical and Experimental Pathology
Publisher:	e-Century Publishing Corporation
Volume:	3
Number of Issue or Book Chapter:	5
Page Range:	pp. 505-514
Date:	25 March 2010
Institutions:	Chemistry and Pharmacy > Institute of Pharmacy > Group Clinical Pharmacy (Dr. Dorn)
Keywords:	Nonalcoholic fatty liver disease (NAFLD), Fatty acid synthase (FASN) , nonalcoholic steatohepatitis (NASH), SREBP1, expression, immunohistochemistry
Dewey Decimal Classification:	600 Technology > 615 Pharmacy
Status:	Published
Refereed:	Yes, this version has been refereed
Created at the University of Regensburg:	Yes
Item ID:	37047

Preview

Export bibliographical data

Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid accumulation which starts with simple hepatic steatosis and may progress toward inflammation (nonalcoholic steatohepatitis [NASH]). Fatty acid synthase (FASN) catalyzes the last step in fatty acid biosynthesis, and thus, it is believed to be a major determinant of the maximal hepatic capacity to generate fatty acids by de ...

Owner only: item control page

Download Statistics

More literature (via CORE)

Details

Preview

Export bibliographical data

Abstract

Abstract

Download Statistics

Downloads

More literature (via CORE)

University Library